Overview

Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy

Status:
Unknown status

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

Phase II trial evaluating the safety and efficacy of oral appliqued niclosamide in patients who are progressive with metachronous or synchronous metastases of colorectal cancer among the previous therapy (Nikolo). Monocentric open-label clinical trial of phase II. All patients received 2 g p.o. niclosamide daily until progression (according to RECIST) or unacceptable toxicity or discontinuation of study for other reasons.

Phase:

Phase 2

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborator:

Center for Molecular Medicine

Treatments:

Niclosamide